Plain-English translation of NCT07352891 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
DigiCare-HFrEF is testing a new digital platform that allows heart failure patients to report their daily symptoms and vital signs (like blood pressure and weight) through a smartphone app. The app uses an algorithm to flag any warning signs and suggests medication adjustments to their doctors, who then review and approve changes before communicating them back to patients. The trial compares this close, technology-enabled approach to standard in-person follow-up care to see which one better prevents hospital readmissions and helps doctors optimize medications.
Many heart failure patients are readmitted to the hospital soon after discharge because their medications aren't adjusted quickly enough and warning signs are missed between doctor visits. This trial exists to see whether real-time daily monitoring and faster communication with clinicians can catch problems earlier and keep patients healthier at home.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to either the digital app group or the standard care group. If you're in the app group, you'll use a smartphone platform to report your symptoms, blood pressure, and weight every day; the app will analyze this information and alert your doctor if there are warning signs, and your doctor will adjust your medications as needed. You'll have a remote check-in at 1 month and an in-person visit at 3 months. If you're in the standard care group, you'll receive usual guideline-based outpatient follow-up without the daily app monitoring. The trial will track how many hospital visits and emergency events occur in each group.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
China